SORRENTO THERAPEUTICS WKN: A1W8DY ISIN: US83587F2020 Kürzel: SRNE Forum: Aktien Thema: Hauptdiskussion
Sorrento Therapeutics, Inc. (NASDAQ:SRNE) is a San Diego, California-based biotech company developing treatments for cancer, intractable pain, and COVID-19. The company has eight manufacturing sites, five in the US and three in China. ADVERTISEMENT In a research note issued to investors on November 2, Brandon Folkes at Cantor Fitzgerald started coverage on Sorrento Therapeutics, Inc. (NASDAQ:SRNE) with a target price of $5 and assigned the stock an Overweight rating. The target price reflects a handsome upside potential of 284% from the closing price as of December 7. In August, the drug candidate SP-103 from Scilex, Sorrento Therapeutics, Inc.'s (NASDAQ:SRNE) majority-owned subsidiary, was given fast-track status by the U.S. Food and Drug Administration (FDA). The drug is targeted toward the treatment of severe low back pain (LBP). Folkes believes that Sorrento Therapeutics, Inc. (NASDAQ:SRNE) has the ability to develop multiple best-in-class products in high-value fields of oncology, non-opioid pain relief, and infectious diseases like COVID-19. Experts think Sorrento Therapeutics, Inc. (NASDAQ:SRNE) is trading at a significant valuation discount compared to its rivals, making it one of the best small-cap stocks to invest in.
Sorrento Therapeutics, Inc. (NASDAQ:SRNE) is a San Diego, California-based biotech company developing treatments for cancer, intractable pain, and COVID-19. The company has eight manufacturing sites, five in the US and three in China. ADVERTISEMENT In a research note issued to investors on November 2, Brandon Folkes at Cantor Fitzgerald started coverage on Sorrento Therapeutics, Inc. (NASDAQ:SRNE) with a target price of $5 and assigned the stock an Overweight rating. The target price reflects a handsome upside potential of 284% from the closing price as of December 7. In August, the drug candidate SP-103 from Scilex, Sorrento Therapeutics, Inc.'s (NASDAQ:SRNE) majority-owned subsidiary, was given fast-track status by the U.S. Food and Drug Administration (FDA). The drug is targeted toward the treatment of severe low back pain (LBP). Folkes believes that Sorrento Therapeutics, Inc. (NASDAQ:SRNE) has the ability to develop multiple best-in-class products in high-value fields of oncology, non-opioid pain relief, and infectious diseases like COVID-19. Experts think Sorrento Therapeutics, Inc. (NASDAQ:SRNE) is trading at a significant valuation discount compared to its rivals, making it one of the best small-cap stocks to invest in.
Mehr zu diesem Wert
|
|
Thema | ||
|---|---|---|---|
| 1 | SORRENTO THERAPEUTICS Hauptdiskussion | ||
| 2 | SORRENTO INFORMATIV | ||
| 3 | Sorrento, Spam frei!! | ||
| 4 | Ausschließlich Sorrento News | ||
| 5 | Never Surrender ✌️ |
|
|
Thema | ||
|---|---|---|---|
| 1 | BAYER Hauptdiskussion | -0,23 % | |
| 2 | BLOOM ENERGY A Hauptdiskussion | +4,12 % | |
| 3 | Trading- und Aktien-Chat | ||
| 4 | für alle, die es ehrlich meinen beim Traden. | ||
| 5 | Diginex | -11,02 % | |
| 6 | Ideen zu Ausbrüche, Abpraller, mögliche Einstiege | -3,32 % | |
| 7 | Poet Technologies | -49,74 % | |
| 8 | NANO ONE MATERIALS Hauptdiskussion | +0,58 % | |
| 9 | Volatus Aerospace (Offener Austausch) | -2,28 % | |
| 10 | Tungsten West Hauptdiskussion | +1,47 % | Alle Diskussionen |
|
|
Thema | ||
|---|---|---|---|
| 1 | BAYER Hauptdiskussion | -0,23 % | |
| 2 | BLOOM ENERGY A Hauptdiskussion | +4,12 % | |
| 3 | Diginex | -11,02 % | |
| 4 | Ideen zu Ausbrüche, Abpraller, mögliche Einstiege | -3,32 % | |
| 5 | Poet Technologies | -49,74 % | |
| 6 | NANO ONE MATERIALS Hauptdiskussion | +0,58 % | |
| 7 | Volatus Aerospace (Offener Austausch) | -2,28 % | |
| 8 | Tungsten West Hauptdiskussion | +1,47 % | |
| 9 | SHELL Hauptdiskussion | +3,83 % | |
| 10 | Plaid Technologies Hauptdiskussion | +120,64 % | Alle Diskussionen |